The purpose of the meeting will be to discuss the need for improved cognitive and functional outcome measures for clinical trials of patients diagnosed with MCI due to AD and preclinical Alzheimer's Disease. Recent publications of the NIA-AA Revised Criteria for AD and the FDA Guidance for Industry on Developing Drugs for the Treatment of Early Stage AD reflect the urgency for testing new interventions earlier in the disease process. In order to facilitate the planning and initiation of new trials in pre-dementia populations, more sensitive ways to measure cognitive and functional change in a clinical trial setting are needed to evaluate treatment efficacy and inform clinical meaningfulness. Furthermore, the possibility of using a biomarker in the future to determine treatment effects will be dependent on a demonstration of clinical benefit.  This meeting will focus on: 1) the application of existing cognitive and functional outcome measures to the study of preclinical and early MCI populations, 2) gaps and opportunities in current measurement approaches for early AD populations and 3) next steps necessary to move the field closer to much needed outcome measures that optimally quantify a treatment benefit for patients in the preclinical AD to early MCI stages of the disease. Strategies for helping trials move forward in the near-term as well as more tailored, long-term solutions will be explored.